Optimi Health Corp. - Chief Science Officer, Justin Kirkland
Chief Science Officer, Justin Kirkland
Source: Dailyadvent
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Optimi Health Corp. (OPTI) submits a second patent for a two-part processing method involving the extraction and delivery of psilocybin active components
  • The two-part extraction process uses a highly viscous material to isolate key components of psychedelic mushrooms
  • The unique part of this process is that it is performing two different functions with a single unique component
  • The repulsion technology pushes the active ingredient through the layers of skin, and treatment begins shortly after application
  • Optimi Health Corp. (OPTI) is up 4.26 per cent trading at $0.49 per share as of 12:56 p.m. EST

Optimi Health Corp. (OPTI) has submitted a second patent for a two-part processing method involving the extraction and delivery of psilocybin active components.

The two-part extraction process uses a highly viscous material to isolate key components of psychedelic mushrooms.

It then dissolves the psilocybin into a molecular solution.

Using the same energy, the active ingredients are then ‘repelled’ into the skin when applied topically.

Due to the skin’s highly permeable membrane, the solution allows for a more sustained release into the body.

It also provides a patient with the ability to experience the desired outcome for longer periods of time.

The unique part of this process is that it is performing two different functions with a single unique component.

Justin Kirkland, Chief Science Officer of Optimi, Stated,

“We leverage this energy to perform two functions; first, the attraction energy will extract psilocybin out of the mushroom; second, when this same material is applied to the skin, it will advance the drug through the skin and into the bloodstream.”

The solution can be loaded into Optimi’s drug delivery system for direct passage through the skin into the bloodstream.

Transdermal application avoids the degradation of psilocybin by the liver that occurs with traditional oral drug delivery.

Optimi’s delivery system is designed to require no additional shuttling agents.

The repulsion technology pushes the active ingredient through the layers of skin, and treatment begins shortly after application.

This new process will help to reduce costs and resources while providing patients with a superior product.

Optimi Health Corp. (OPTI) is up 4.26 per cent trading at $0.49 per share as of 12:56 p.m. EST.

More From The Market Herald

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.

" Nirvana Life Sciences Inc (CSE:NIRV) signs LOI with Innovate Phytotechnologies Inc

Nirvana Life Sciences (NIRV) has  signed a letter of intent with Innovate Phytotechnologies Inc. (INVP)
Clearmind Medicine - CEO, Adi Zuloff Shani.

" Clearmind Medicine (CSE:CMND) announces upcoming pre-IND meeting with the FDA

Clearmind (CMND) will participate in a pre-IND meeting with the FDA on May 18, 2022.
Red Light Holland - Advisor, Akwasi Owusu Bempah.

" Red Light Holland (CSE:TRIP) adds Akwasi Owusu-Bempah to Advisory Board

Red Light Holland (TRIP) has hired drug law expert Akwasi Owusu-Bempah as its newest advisor.